Open beta · everything is free with an account while we build. Founding accounts get preferred pricing when paid plans arrive. Create yours →
SE

STU EVENHAUGEN

FRESENIUS KABI USA LLC · Lake Zurich, IL
Registered · LDAActive

At a glance

Works on
Professional highlights appear here once this profile is claimed. Claim it →

Background

Career
Lake Zurich, IL · current

The past 12 months

Clients
1
past 12 months
Filings
2
past 12 months
Agencies contacted
Centers For Medicare and Medicaid Services (CMS)Commerce, Dept of (DOC)Defense, Dept of (DOD)Food & Drug Administration (FDA)HOUSE OF REPRESENTATIVESHealth & Human Services, Dept of (HHS)Labor, Dept of (DOL)Natl Economic Council (NEC)Patent & Trademark Office (PTO)SENATEU.S. Trade Representative (USTR)Veterans Affairs, Dept of (VA)White House Office

Specific issues

Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
Manufacturing · 2026 Q1
Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
Trade (domestic/foreign) · 2026 Q1
S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement
Health Issues · 2026 Q1

Clients

2026 · 2 filings
$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings2
2026 Q1
FRESENIUS KABI USA LLC
1Alda.gov →
2026 Q1
FRESENIUS KABI USA LLC
Q1lda.gov →